Regulatory considerations in oncologic biosimilar drug development

Biosimilar monoclonal antibodies are being developed globally for patients with different types of solid tumors and hematologic malignancies. Applications for proposed biosimilar monoclonal antibodies are being submitted to the regulatory authorities around the world and may increase patient access...

Descripción completa

Detalles Bibliográficos
Autores principales: Macdonald, Judith C, Hartman, Helen, Jacobs, Ira A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622730/
https://www.ncbi.nlm.nih.gov/pubmed/25961747
http://dx.doi.org/10.1080/19420862.2015.1040973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622730/
https://www.ncbi.nlm.nih.gov/pubmed/25961747
http://dx.doi.org/10.1080/19420862.2015.1040973

Ejemplares similares